Human Immune Response to Influenza Neuraminidase After Vaccination: A Systematic Review [0.03%]
疫苗接种后人体对流感神经氨酸酶的免疫反应：系统评价
Vardhini Ganesh,Justin Iampietro,Saranya Sridhar et al.
Vardhini Ganesh et al.
Background: Licensed influenza vaccines primarily target hemagglutinin (HA)-related immunity, but neuraminidase (NA)-based immunity is gaining attention as an independent correlate of protection. Inactivated influenza vac...
Global Estimates of COVID-19 Morbidity and Mortality: A Cohort Study and Mathematical Model Analysis [0.03%]
全球COVID-19发病和死亡人数估计值：群组研究和数学模型分析
Houssein H Ayoub,Hiam Chemaitelly,Laith J Abu-Raddad
Houssein H Ayoub
Background: The true extent of the severity and fatality caused by the COVID-19 pandemic remains uncertain. This study provides an approximate estimate of the global disease burden from the pandemic. ...
Prevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011-2020 NHANES Data [0.03%]
基于2011至2020年美国全国健康和营养调查数据的成人呼吸道合胞病毒严重疾病的危险因素及其发病年龄分布分析
Emily K Horn,David Singer,Alison Booth et al.
Emily K Horn et al.
Background: Respiratory syncytial virus (RSV) vaccines are approved in the United States (US) among adults ≥ 60 years of age (YoA). Understanding disparities in risk factors (RFs) for severe RSV disease by social determi...
Nirsevimab Effectiveness Against RSV-Related Hospitalisations in Children Under 24 Months: A Test-Negative Case-Control Study in Portugal, 2024-2025 [0.03%]
2024-2025年葡萄牙小于24个月儿童中 nirsevimab 对抗RSV相关住院的有效性：一项针对检测阴性病例对照的研究
Vânia Gaio,Camila Henriques,Miguel Lança et al.
Vânia Gaio et al.
We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)-related hospitalisation in eligible children (< 2 years) using a test-negative case-control design within the VigiRSV network (weeks 43/2024 to 16/2025). Am...
The Epidemiology, Phylogeny, and Strain Antigenicity of an Influenza A/H3N2 Virus Outbreak Among Vaccinated US Navy Midshipmen [0.03%]
一种流感A/H3N2病毒在接种疫苗的美国海军学员中爆发的流行病学、系统发育和菌株抗原性
Simon D Pollett,Emily Hone,Stephanie A Richard et al.
Simon D Pollett et al.
We performed epidemiological, genetic, and antigenic characterization of an influenza A/H3N2 outbreak in a congregate setting of young adults with high vaccination rates. We noted substantial duty-days lost, rapid spread, and vaccine antige...
Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study [0.03%]
2023年秋季XBB.1.5新冠助推疫苗在2024年夏季欧盟/欧洲经济区的有效性：VEBIS电子健康记录网络研究
James Humphreys,Nathalie Nicolay,Toon Braeye et al.
James Humphreys et al.
Background: After a period of low SARS-CoV-2 activity, viral circulation increased in Europe from May 2024, driven by immune-evasive KP sublineages of the JN.1 variant. We estimated vaccine effectiveness (VE) of the XBB.1...
Demographic Analysis of Mortality Changes Associated With the COVID-19 Pandemic in Japan, 2020-2022 [0.03%]
日本2020至2022年与COVID-19大流行相关的死亡变化的人口统计分析
Yuta Okada,Hiroshi Nishiura
Yuta Okada
Backgrounds: Demographic analysis is required to thoroughly evaluate the mortality impact of COVID-19 in Japan that cannot be captured by epidemiological surveillance. ...
Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation in England: 2022/2023 and 2023/2024 Seasons [0.03%]
英国流感疫苗的效果及预防住院保护期的持续时间：2022/2023和2023/2024季节
Heather J Whitaker,Freja C M Kirsebom,Katie Hassell et al.
Heather J Whitaker et al.
Background: Linkage of national, healthcare data can provide greater resolution of vaccine effectiveness (VE) against influenza subtypes, as well as the relative effectiveness of different vaccine types and the effects of...
COVID-19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024-May 2025 [0.03%]
2024年9月至2025年5月欧洲VEBIS医院网络中老年人新冠疫苗预防住院的有效性研究
Madelyn Rojas-Castro,Nuno Verdasca,Susana Monge et al.
Madelyn Rojas-Castro et al.
We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test-negative, case-control study across seven sites in ...
Multicenter Study
Influenza and other respiratory viruses. 2025 Nov;19(11):e70191. DOI:10.1111/irv.70191 2025
Detection of Antibodies Specific to H5 Avian Influenza Virus in a Sheep in Norway, June 2024, 11 Months After an Outbreak of Highly Pathogenic Avian Influenza in a Nearby Seabird Colony [0.03%]
挪威发现羊感染H5型高致病性禽流感病毒抗体，距离附近海鸟群爆发疫情已过去11个月，2024年6月检测结果公布
Johanna Hol Fosse,Grim Rømo,Francesco Bonfante et al.
Johanna Hol Fosse et al.
A 2023 outbreak of highly pathogenic avian influenza in seabirds in Norway caused substantial environmental contamination of grazing areas frequented by local sheep. Eleven months later, 220 sheep were tested for antibodies to type A influe...